Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Diagnostic value of SARS-CoV-2 RDT-Ab with RT-PCR: Secondary data at Diponegoro National Hospital

Journal of Biomedicine and Translational Research · Vol. 8 No. 1 (2022) · hlm. 21–25

DOI
10.14710/jbtr.v1i1.13759
ISSN
2503-2178
Terbit
2022-04-28
Penerbit
Faculty of Medicine, Universitas Diponegoro
Bahasa
eng
Lisensi
creativecommons.org/licenses/by-sa/4.0

Abstrak

Background: The SARS-CoV-2 rapid diagnostic test antibody (RDT-Ab) was most often used as an early detection tool for COVID-19 at the beginning of pandemic. Whereas the antibody response was formed in the second week after the onset of symptoms.Objective: To evaluate the diagnostic value of the SARS-CoV-2 RDT-Ab, including sensitivity (Se), specificity (Sp), positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (PLR), and negative likelihood ratio (NLR), in patients at Diponegoro National Hospital, Semarang, Indonesia.Methods: Data subjects have been selected retrospectively using purposive sampling based on inclusion criteria (patients who had shortness of breath, pneumonia, suspected, possible, or confirmed COVID-19, and data on the results of the SARS-CoV-2 RDT-Ab IgM and/or IgG (Leccurate® SARS-CoV-2 Antibody Rapid Test Kit) with a valid RT-PCR as gold standard) and exclusion criteria (patients who only had one of either SARS-CoV-2 RDT-Ab or RT-PCR). Researchers analyzed the diagnostic value of SARS-CoV-2 RDT-Ab with RT-PCR which gave the possibility of true-positive, false-positive, true-negative, and false-negative results arranged in a 2x2 table. According to WHO, the diagnostic value is said to be good at least having a sensitivity value of 80% and specificity of 97%.Results: The diagnostic value of SARS-CoV-2 RDT-Ab with RT-PCR, which was evaluated from 1142 patients retrospectively, included IgM (Se 65.25%, Sp 89.51%, PPV 46.70%, NPV 94.81%, PLR 6.22, NLR 0.39), IgG (Se 58.16%, Sp 93.01%, PPV 53.95%, NPV 94.04%, PLR 8.32, NLR 0.45), IgM and IgG (Se 53.90%, Sp 94.21%, PPV 56.72%, NPV 93.55%, PLR 9.30, NLR 0.49), IgM and/or IgG (Se 69.50%, Sp 88.31%, PPV 45.58%, NPV 95.36%, PLR 5.95, NLR 0.35).Conclusion: SARS-CoV-2 RDT-Ab (Leccurate® SARS-CoV-2 Antibody Rapid Test Kit) is not ideal to be used as a rapid diagnostic test for COVID-19.Keywords: COVID-19, Rapid diagnostic test, RT-PCR, SARS-CoV-2 antibody

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 118 tautan kepenulisan bersama · 36 lintas organisasi · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Diponegoro University
  • Eijkman Institute for Molecular Biology
  • Universitas Jambi
  • State University of Semarang
  • National Research and Innovation Agency
  • Jenderal Soedirman University
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Udin BahrudinDiponegoro University3
Etika Ratna NoerDiponegoro University2
Faizah FulyaniDiponegoro University2
Herera RahajengDiponegoro University1
Awal PrasetyoDiponegoro University1
Neni SusilaningsihDiponegoro University1
Udadi SadhanaDiponegoro University1
Hairul AsriDiponegoro University1
Maria Estela KarolinaUniversitas Jambi1
Mujahidah MujahidahAfiliasi tidak diketahui1
Subakir SubakirAfiliasi tidak diketahui1
Edi DharmanaDiponegoro University1
Jonathan Alvin Nugraha HalimDiponegoro University1
Stefanie Natalia HalimDiponegoro University1
Dionisius DenisEijkman Institute for Molecular Biology1
Sotianingsih HaryantoUniversitas Jambi1
R. Tedjo SasmonoEijkman Institute for Molecular Biology1
Benediktus YohanEijkman Institute for Molecular Biology1
Thania Lathifatunnisa Putri AgustiDiponegoro University1
Nahwa ArkhaesiDiponegoro University1
Anugrah RiansariDiponegoro University1
Qonita Nur QolbyState University of Semarang1
Muflihatul MunirohDiponegoro University1
Julian DewantiningrumDiponegoro University1
Besari Adi PramonoDiponegoro University1
Eka Djatnika NugrahaNational Research and Innovation Agency1
Irfan KesumayadiDiponegoro University1
Desvita SariDiponegoro University1
Dwi Utami AnjarwatiJenderal Soedirman University1
Nesia Hani AlfiyulianiDiponegoro University1
Mujahidah MujahidahDiponegoro University1
Iva Puspita SariDiponegoro University1
Purnomo HadiDiponegoro University1
Rayvita AN MeagratiaDiponegoro University1
Ferdy Kurniawan CayamiDiponegoro University1
Wiwik LestariDiponegoro University1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://ejournal2.undip.ac.id/index.php/jbtr/oai, pertama di-harvest 9 Nov 2026, terakhir terlihat 9 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Diagnostic value of SARS-CoV-2 RDT-Ab with RT-PCR: Secondary data at Diponegoro National Hospital</dc:title>
	<dc:creator>Satyagraha, Muhammad Thifan</dc:creator>
	<dc:creator>Maharani, Nani</dc:creator>
	<dc:creator>Hapsari, Rebriarina</dc:creator>
	<dc:creator>Hendrianingtyas, Meita</dc:creator>
	<dc:subject xml:lang="en-US">COVID-19; Rapid diagnostic test; RT-PCR; SARS-CoV-2 antibody</dc:subject>
	<dc:description xml:lang="en-US">Background: The SARS-CoV-2 rapid diagnostic test antibody (RDT-Ab) was most often used as an early detection tool for COVID-19 at the beginning of pandemic. Whereas the antibody response was formed in the second week after the onset of symptoms.Objective: To evaluate the diagnostic value of the SARS-CoV-2 RDT-Ab, including sensitivity (Se), specificity (Sp), positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (PLR), and negative likelihood ratio (NLR), in patients at Diponegoro National Hospital, Semarang, Indonesia.Methods: Data subjects have been selected retrospectively using purposive sampling based on inclusion criteria (patients who had shortness of breath, pneumonia, suspected, possible, or confirmed COVID-19, and data on the results of the SARS-CoV-2 RDT-Ab IgM and/or IgG (Leccurate® SARS-CoV-2 Antibody Rapid Test Kit) with a valid RT-PCR as gold standard) and exclusion criteria (patients who only had one of either SARS-CoV-2 RDT-Ab or RT-PCR). Researchers analyzed the diagnostic value of SARS-CoV-2 RDT-Ab with RT-PCR which gave the possibility of true-positive, false-positive, true-negative, and false-negative results arranged in a 2x2 table. According to WHO, the diagnostic value is said to be good at least having a sensitivity value of 80% and specificity of 97%.Results: The diagnostic value of SARS-CoV-2 RDT-Ab with RT-PCR, which was evaluated from 1142 patients retrospectively, included IgM (Se 65.25%, Sp 89.51%, PPV 46.70%, NPV 94.81%, PLR 6.22, NLR 0.39), IgG (Se 58.16%, Sp 93.01%, PPV 53.95%, NPV 94.04%, PLR 8.32, NLR 0.45), IgM and IgG (Se 53.90%, Sp 94.21%, PPV 56.72%, NPV 93.55%, PLR 9.30, NLR 0.49), IgM and/or IgG (Se 69.50%, Sp 88.31%, PPV 45.58%, NPV 95.36%, PLR 5.95, NLR 0.35).Conclusion: SARS-CoV-2 RDT-Ab (Leccurate® SARS-CoV-2 Antibody Rapid Test Kit) is not ideal to be used as a rapid diagnostic test for COVID-19.Keywords: COVID-19, Rapid diagnostic test, RT-PCR, SARS-CoV-2 antibody</dc:description>
	<dc:publisher xml:lang="en-US">Faculty of Medicine, Universitas Diponegoro</dc:publisher>
	<dc:date>2022-04-28</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en-US"></dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ejournal2.undip.ac.id/index.php/jbtr/article/view/13759</dc:identifier>
	<dc:identifier>10.14710/jbtr.v1i1.13759</dc:identifier>
	<dc:source xml:lang="en-US">Journal of Biomedicine and Translational Research; Vol 8, No 1 (2022): April 2022; 21-25</dc:source>
	<dc:source>2503-2178</dc:source>
	<dc:source>10.14710/jbtr.v1i1</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ejournal2.undip.ac.id/index.php/jbtr/article/view/13759/7151</dc:relation>
	<dc:relation>https://ejournal2.undip.ac.id/index.php/jbtr/article/downloadSuppFile/13759/3314</dc:relation>
	<dc:relation>https://ejournal2.undip.ac.id/index.php/jbtr/article/downloadSuppFile/13759/3315</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2022 Journal of Biomedicine and Translational Research</dc:rights>
	<dc:rights xml:lang="en-US">https://creativecommons.org/licenses/by-sa/4.0</dc:rights>
</oai_dc:dc>